Oligonucleotides & Peptides Xchange - Boston - 2026

Quality Control
- Quality Control
15:45 16:45

Stability-Indicating Methods for Backbone-Modified Oligonucleotides: Degradation Pathways and Control Strategy [Topic TBC]

Brooke Koshel, Director of Process Development - Wavelife Sciences
Novel Modalities & Discovery
- Novel Modalities & Discovery
15:10 15:40

Poster Presentation: Thiophosphoramidate Morpholino Oligonucleotides (TMOs): A Novel Class of PMOs compatible With Conventional Automated Oligonucleotide Synthesis
CMC & Process Development
- CMC & Process Development
11:25 12:25

Rethinking Oligonucleotide Synthesis, Toward Greener Pastures? [Topic TBC]
Drug Delivery
- Drug Delivery
11:25 12:25

Advances in imaging to monitor oligonucleotide delivery and target binding
Drug Delivery
- Drug Delivery
09:05 10:05

Beyond the BBB: using AI to rapidly identify and de-risk peptide delivery strategies for CNS targets (Topic TBC)

Peixin Zhu, VP of Editing Discovery - Verve Therapeutics
Quality Control
- Quality Control
15:10 15:40

Poster Presentation: Advancing automation and digital systems in oligonucleotide manufacturing
CMC & Process Development
- CMC & Process Development
15:10 15:40

Poster Presentation: Manufacturing the next wave: CMC evolution for extrahepatic oligonucleotides
CMC & Process Development
- CMC & Process Development
09:05 10:05

CMC Analytical Considerations and Challenges for Oligonucleotides and Oligonucleotide-conjugates

Analytical techniques, considerations and gaps supporting oligonucleotide and oligonucleotide-conjug ...

Hongling Han, , Senior Director, Head of Analytical Development and QC - PepGen
Quality Control
- Quality Control
09:05 10:05

Purification bottlenecks after solid phase synthesis, strategies for managing highly impure or difficult peptides [Topic TBC]

Rowshan Alam, Vice President, Head of Chemistry (Medicinal, Process, and In-process Analytics - Prime Medicine Inc
Novel Modalities & Discovery
- Novel Modalities & Discovery
09:05 10:05

Engineering Ionizable Lipids and LNPs for Improved Oligonucleotide Delivery: From Endosome Escape to Biocompatibility [Topic TBC]

Dmitry Samarsky, Co-Founder & CSO - ARNAgen Therapeutics
Quality Control
- Quality Control
11:25 12:25

Ensuring robust QC processes during manufacturing and scaling
Drug Delivery
- Drug Delivery
15:45 16:45

Unlocking broader therapeutic applications of siRNA through innovative delivery strategies

Jordan Lewandowski, Director of Biology - Flagship Labs
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
15:00 15:10

Afternoon Refreshments
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
14:00 14:30

1-2-1 Meetings/Networking Break
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
16:45 17:45

Evening Drinks Reception
Drug Delivery
- Drug Delivery
15:10 15:40

Poster Presentation: Cross modality strategies for delivering oligonucleotides and peptides
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
13:25 13:55

Spotlight Presentation: PolyPeptide
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
14:30 15:00

1-2-1 Meetings/Networking Break
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
08:30 09:00

Opening Address & Keynote Presentation:
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
12:25 13:25

Networking Lunch
Novel Modalities & Discovery
- Novel Modalities & Discovery
11:25 12:25

Bridging discovery to first-in-human: Overcoming translational bottlenecks for new oligonucleotide drug classes
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
11:15 11:25

Morning Refreshments
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
10:45 11:15

1-2-1 Meetings/Networking Break
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
10:10 10:40

1-2-1 Meetings/Networking Break
- Novel Modalities & Discovery
- Drug Delivery
- CMC & Process Development
- Quality Control
08:00 08:30

Registration
CMC & Process Development
- CMC & Process Development
15:45 16:45

Future application of novel manufacturing oligonucleotide synthesis approaches and considerations for oligo-based

Overview of current and advanced delivery technologies such as LNP, AAV, conjugations, polymeric etc ...

Harsh Chauhan, Director, Formulation Development and External Manufacturing - Alltrna
Novel Modalities
- Novel Modalities & Discovery
15:45 16:45

Novel Modalities through AI Enabled Peptide Oligo Conjugate Engineering, From Concept to Lead Candidate